Latest News & Features
Refine Search
Americas
As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper 27 January 2026
Americas
The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent. 26 January 2026
Careers
The new recruit has a “stellar track record” of representing big tech in trade secret and patent litigation, and joins the firm’s newly opened San Francisco office. 26 January 2026
Americas
Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies. 23 January 2026
Americas
A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent. 22 January 2026
Americas
New rankings from LSIPR’s sister title spotlight the firms and lawyers that are most successfully navigating the volatile world of trade secrets, from ‘prompt injections’ to billion-dollar retrials. 22 January 2026
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler. 22 January 2026
Careers
Orrick, Herrington & Sutcliffe adds senior litigators with experience in patent, trade secret, copyright, trademark, and commercial disputes across life sciences and technology. 22 January 2026
Americas
The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions. 21 January 2026
Asia
Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector. 20 January 2026


